BLCO may be sold in 2025 to service the debt of majority shareholder BHC, and any sale will be at a premium to the current ...

Clinical-stage drug development offers big rewards—and big risks. | This week on "The Top Line," we dive into several of the ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...